Pagina principale
Analisi dell'app gratuita
WHO Contraception tool
WHO Contraception tool Vs. ASCCP Management Guidelines

WHO Contraception tool vs. ASCCP Management Guidelines Utilizzo e statistiche

This tool is the digital version of the MEC Wheel. It contains the medical eligibility criteria for starting use of contraceptive methods, based on Medical Eligibility Criteria for Contraceptive Use, 5th edition (2015), one of WHO’s evidence-based guidelines. It guides family planning providers in recommending safe and effective contraception methods for women with medical conditions or medically-relevant characteristics. The tool includes recommendations on initiating use of nine common types of contraceptive methods: 1. Combined pills, COC (low dose combined oral contraceptives, with ≤ 35 μg ethinyl estradiol) 2. Combined contraceptive patch, P 3. Combined contraceptive vaginal ring, CVR 4. Combined injectable contraceptives, CIC 5. Progestogen-only pills, POP 6. Progestogen-only injectables, DMPA (IM,SC)/NET-EN (depot medroxyprogesterone acetate intramuscular or subcutaneous or norethisterone enantate intramuscular) 7. Progestogen-only implants, LNG/ETG (levonorgestrel or etonogestrel) 8. Levonorgestrel-releasing intrauterine device, LNG-IUD 9. Copper-bearing intrauterine device, Cu-IUD

App Store di Apple
Gratis
Settore Medico

Classifica degli store

- -

ASCCP Management Guidelines

The ASCCP Risk-Based Management Consensus Guidelines provide evidence-based recommendations for managing abnormal cervical cancer screening results and cancer precursors, including post-colposcopy and post-treatment scenarios. ASCCP is pleased to offer this app to streamline navigation of the ASCCP Risk-Based Management Consensus Guidelines for abnormal cervical cancer screening tests and cancer precursors. The guidelines articles, as published in the Journal of Lower Genital Tract Disease, as well as the comprehensive risk estimates, can be accessed through https://www.asccp.org/guidelines. These evidence-based management guidelines, initially developed in 2019, came together through a consensus process of 19 organizations. The updated management guidelines aim to: • Allow for a more complete and precise estimation of risk • Provide more appropriate intervention for high-risk individuals (detect and treat more precancer) • Recommend less intervention for low-risk individuals (decrease testing and treatment that won’t prevent cancer and may cause reproductive harm) • Allow for the future addition of new risk modifiers and screening and management technologies See https://www.asccp.org/UserGuide for tips on using the app.